Biocon Biologics Ltd is aiming to expand its insulin portfolio in the US market, as global innovators focus on more lucrative anti-obesity GLP-1 therapies.

Biocon Ltd's biosimilar arm, which holds a 15–17% share in the US insulin market, recently announced it will supply insulin glargine pens to US-based non-profit Civica, which will commercialize them at low cost in California. Also Read | Why India is making preventive healthcare a must for future doctors

Under a multi-year exclusive distributorship agreement announced on 16 October, Biocon Biologics will manufacture and supply insulin glargine pens to Civica, which will commercialize them under the Bengaluru-based firm's existing marketing approval through a private-label arrangement.

Civica will distribute, promote, and sell

See Full Page